30-09-2011 | CE certification 

JenaValve Technology GmbH is first in receiving CE certification for a true second generation transapical TAVI system
Download: CE Certification.pdf 

30-01-2011 | JenaValve™ reports significant clinical milestone

First-ever successful transcatheter implantation of a 27mm transapical aortic valve prosthesis
Download: Significant clinical milestone.pdf

25-05-2010 | JenaValve Technology Reports Nine Successful Human Implantations of its Transapical TAVI System

Download: Successful Human Implantations.pdf

01-04-2010| JenaValve Closes € 19 Million Series B Financing Round

Download: Series B Financing.pdf 

28-04-2009| JenaValve Names Michael J. Dormer as Chairman of the Board

Download: JenaValve Names Michael J. Dormer as Chairman.pdf 

21-09-2007 | JenaValve Closes 10 Million euro Series A-2 Financing Round 

Download: Series A-2 Financing Round.pdf 

Timeline

2011

  • Transapical device for commercialization.
  • Animal trial for transfemoral device.
  • CE Mark attributed to JenaValve TAVI.

 2010 

  • Series B financing round completed.
  • Relocation to larger premises to prepare European market entry.

 2009 

  • Transapical FIM initiated.
  • Michael J. Dormer appointed Chairman of the Board.
  • Temporary human implants completed.
  • Series B fund-raising initiated. 

2008 

  • Organization strengthened with key personnel. 
  • Animal trials completed.
  • Major steps achieved in valve development.
  • Transapical system completed.

 2007 

  • Scientific Advisory Board established.
  • Secured Series A-2 financing round with EdRIP (lead investor), Atlas Venture and NeoMed Management.
  • Acute animal trials conducted.First temporary human implant.

 2006 

  • Series A-1 financing round completed with Atlas Venture.
  • Management team established.
  • Design of delivery systems (transapical and transfemoral) initiated.
  • New prosthesis design with biological valve initiated.